Universiteit Leiden

nl en

Michiel van de Sande

Professor Orthopaedics

Name
Prof.dr. M.A.J. van de Sande
Telephone
+31 71 526 3606
E-mail
m.a.j.van_de_sande@lumc.nl
ORCID iD
null

Michiel van de Sande is professor of orthopedic oncology, in particular pediatric orthopedic oncology, at the orthopedics department at the LUMC and works as an oncological pediatric orthopedic surgeon at the Princess Maxima Center for Pediatric Oncology. He is Chairman of the Bone Tumors and Infection Working Group of the EPOS and a board member of the Dutch Sarcoma Group, FOSTER and EuroEwing and the EMSOS. His surgical specialty focuses on the treatment of pediatric, AYA and adult patients with bone and soft tissue sarcomas. Within the LUMC Cancer research line, research within oncological orthopedics focuses on (inter)national collaboration; such as multicenter studies on giant cell tumors of the joint and bone, soft tissue sarcomas, chondrosarcomas, adamantinoma, osteo- and Ewing sarcomas.

More information about Michiel van de Sande

Michiel van de Sande is professor of orthopedic oncology, in particular pediatric orthopedic oncology, at the orthopedics department at the LUMC and works as an oncological pediatric orthopedic surgeon at the Princess Maxima Center for Pediatric Oncology. He is Chairman of the Bone Tumors and Infection Working Group of the EPOS and a board member of the Dutch Sarcoma Group, FOSTER and EuroEwing and the EMSOS. His surgical specialty focuses on the treatment of pediatric, AYA and adult patients with bone and soft tissue sarcomas. Within the LUMC Cancer research line, research within oncological orthopedics focuses on (inter)national collaboration; such as multicenter studies on giant cell tumors of the joint and bone, soft tissue sarcomas, chondrosarcomas, adamantinoma, osteo- and Ewing sarcomas.

Michiel van de Sande has published more than 250 peer-reviewed articles and book chapters; His research is funded by several scientific grants; e.g. the KWF, Alpe-D'huZes, Bontius Foundation and Team Westland Foundation EVA.

Orthopedic oncology

Van de Sande has been appointed professor of Orthopedics, in particular pediatric orthopedic oncology, as of May 2020. In his inaugural lecture 'The art of doing and doing nothing' he explored both the practical and philosophical aspects of shared decision-making within sarcoma care.

His research line focuses mainly on the treatment and outcomes of sarcomas in the joint, bones and soft tissues. In recent decades, the prognosis of sarcoma patients has improved little. There are several reasons for this, including the lack of a global patient database. To address this problem, Van de Sande focuses on multicenter studies: “By combining data from healthcare units around the world, we can base prognosis prediction models on larger patient populations, making the models more accurate. This allows us to better translate general treatment options to the individual patient.”

Academic career

Michiel van de Sande completed his medical training at the University of Utrecht and his training as an orthopedic surgeon and his PhD research at the University of Leiden. The title of his dissertation (2008) is 'Rotator Cuff Degeneration in the Rheumatoid Shoulder'. Van de Sande subsequently specialized further in oncological orthopedics at the LUMC in Leiden and the Nuffield Medical Center in Oxford. He was appointed professor of Orthopedics at the Leiden University Medical Center in May 2020.

Professor Orthopaedics

  • Faculteit Geneeskunde
  • LUMC - Medische Faculteit Leiden
  • Divisie 1
  • Orthopedie

Work address

LUMC Main Building
Albinusdreef 2
2333 ZA Leiden

Contact

Publications

  • EPOS bone tumor study group / EuroEwing Consortium Chair / Boardmember and organisor of webbin
  • Dutch Sarcoma Group Bestuurslid, bestuursactiviteit voor de stichting DSG
  • WeBOT NOV Bestuurslid, bestuursactiviteit voor de stichting WeBOT van de NOV
  • Advisoiy Board Member voor Daichii Sanlcyo, Diciphera, LiveMAxLabs Providing Medical background and Reserach advise for clinical trials concerning anti-CSFl in TG
  • Advisory Board Member voor Daichii Sankyo, Diciphera, LiveMAxLabs Providing Medical background and Reserach advise for clinical trials concerning anti-CSF1 in TGCT Pa
This website uses cookies.  More information.